glp-1 drugs pharmaceutical companies 2025 Novo cuts prices 70%, but semaglutide revenue could grow in 2026 3 Companies at the Forefront

S., Fukushima, Y., Lingvay, I., Macura, S., Sndergaard, A

The Bridge gives them one for the next 18 months

Semaglutide versus placebo in patients with heart failure and mildly reduced or preserved ejection fraction: A pooled analysis of the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM randomised trials

Exenatide-induced eosinophilic sclerosing lipogranuloma at the injection site

Al-Aly emphasized that his study also highlighted potential downsides to the medications, including an increased risk of gastrointestinal problems such as nausea, vomiting, diarrhea, and in rare cases paralysis of the stomach

Published June 24, 2023